29 March 2017
: Case report
Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Maria Cristina Maggio1ACDEF*, Giovanni Corsello1CF, Eugenia Prinzi1BF, Rolando Cimaz2ACDEFDOI: 10.12659/AJCR.902351
Am J Case Rep 2017; 18:317-319
Abstract
BACKGROUND: Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs.
CASE REPORT: We describe the clinical case of an 11-year-old girl with SLE. She showed bullous skin lesions with arthralgia, mild proteinuria, resolved after steroid treatment. At the tapering of her prednisone dose, the patient had new skin lesions requiring an increased dose of prednisone. She started dapsone at the dosage of 1 mg/kg/day, maintaining low dose prednisone; this treatment was successfully followed by the dramatic disappearance of skin lesions and limb pain.
CONCLUSIONS: Bullous skin lesions can represent the first clinical presentation of pediatric SLE and could influence the treatment and the outcome of these patients. This case showed an atypical course as both skin manifestations and arthritis promptly and persistently resolved with dapsone without the use of high-dose glucocorticoids. Only a few cases of patients with SLE associated with bullous pemphigoid have been reported in the literature, and very few in the pediatric population.
Keywords: dapsone, Lupus Erythematosus, Systemic, Pemphigoid, Bullous
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945852
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944817
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946074
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946165
Most Viewed Current Articles
21 Jun 2024 : Case report
89,036
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,209
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,680
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,688
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030